SEPNHealthcare · BiotechnologyThe 10 Wall Street analysts covering Septerna, Inc. hold a median 12-month price target of $51 — +27.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Septerna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Volatility (32): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SEPN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +27.5% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | JP Morgan | Maintains | Overweight | $38 → $48 |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | $43 → $62 |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $60 |
| 12 Aug 2026 | Wells Fargo | Maintains | Overweight | $48 → $50 |
| 11 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 11 Aug 2026 | Guggenheim | Maintains | Buy | $45 → $51 |
| 1 July 2026 | Guggenheim | Maintains | Buy | — |
| 1 July 2026 | Guggenheim | Maintains | Buy | $52 → $45 |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 1 July 2026 | Truist Securities | Maintains | Buy | $35 → $43 |
| 1 July 2026 | Truist Securities | Maintains | Buy | — |
| 8 June 2026 | Raymond James | Maintains | Strong Buy | — |
| 13 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 11 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 3 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright& Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SEPN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 10% of US stocks
Cheaper than 23% of US stocks
Cheaper than 91% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 16% of US stocks
Higher than 14% of US stocks
Higher than 38% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Septerna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Septerna, Inc. reported a Q2 loss of $0.29 per share, narrower than the Zacks Consensus Estimate of a $0.48 loss and improved from the $0.56 loss a year ago. The results surpassed revenue estimates as well.
Why it matters — SEPN watchers would note that the company's loss came in well below analysts' expectations, indicating better-than-anticipated quarterly performance.
The 10 Wall Street analysts covering Septerna, Inc. have a median 12-month price target of $51, with estimates ranging from $48 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Septerna, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Septerna, Inc. 89 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Septerna, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +27.5% from the last close, and Ticker Nerd's factor model ranks Septerna, Inc. 89 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Septerna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SEPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $62 over the next 12 months.
Septerna, Inc. returned +241.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Septerna Inc. is a clinical-stage biotechnology company specializing in the discovery and development of oral small molecule therapies targeting G protein-coupled receptors (GPCRs).
The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates". Septerna, Inc. reported a Q2 loss of $0.29 per share, narrower than the Zacks Consensus Estimate of a $0.48 loss and improved from the $0.56 loss a year ago. The results surpassed revenue estimates as well.
Septerna Inc. is a clinical-stage biotechnology company specializing in the discovery and development of oral small molecule therapies targeting G protein-coupled receptors (GPCRs). Powered by its proprietary Native Complex Platform, the company unlocks challenging GPCR targets to create novel medicines for patients with significant unmet needs. Its wholly-owned pipeline focuses on three key therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Notable programs include the PTH1R program with oral small molecule Parathyroid Hormone 1 Receptor agonists for hypoparathyroidism; SEP-631, an oral MRGPRX2 negative allosteric modulator for chronic spontaneous urticaria and mast cell-driven diseases; the TSHR program for Graves’ disease and thyroid eye disease; and oral single- and multi-incretin receptor agonists for metabolic disorders like obesity and type 2 diabetes. Septerna Inc. advances a deep portfolio of GPCR-targeted candidates, employing novel mechanistic approaches to address diseases across these fields. Founded in 2019 and headquartered in South San Francisco, California, the company drives innovation in GPCR drug discovery through its industrial-scale platform and expert team.
CEO Dr. Jeffrey T. Finer M.D., Ph.D. · 123 employees · United States · https://septerna.com